XTL Biopharmaceuticals
XTLB
5 hedge funds and large institutions have $242K invested in XTL Biopharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and closing their positions.
25% more funds holding
Funds holding: 4 → 5 (+1)
12% more capital invested
Capital invested by funds: $216K → $242K (+$25.9K)
0.01% less ownership
Funds ownership: 4.4% → 4.39% (-0.01%)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CTC
Central Trust Company
Jefferson City,
Missouri
|
+$190 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$760 |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$61 |
XTLB Hedge Fund Activity: Q4 2023 in Review
5 of the 6,871 institutional investors tracked by Wall St. Rank reported a position in XTL Biopharmaceuticals (XTLB) for Q4 2023, worth a combined $242K — up 12% from $216K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new XTLB positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 2 trimmed.
The largest buyer was Central Trust Company, opening a new position worth an estimated $190. The largest seller was Morgan Stanley, cutting an estimated $760.
- 5 institutional investors held XTL Biopharmaceuticals (XTLB) as of Q4 2023, up from 4 in Q3 2023.
- Funds reported $242K of XTL Biopharmaceuticals stock for Q4 2023, up 12% quarter-over-quarter.
- 1 fund opened new XTL Biopharmaceuticals positions in Q4 2023 and 0 closed out, a net change of +1 holder.
- The largest XTL Biopharmaceuticals buyer in Q4 2023 was Central Trust Company, an estimated $190 added.
- The largest XTL Biopharmaceuticals seller in Q4 2023 was Morgan Stanley, an estimated $760 sold.
Based on aggregated 13F filings for Q4 2023.